

# CITATION REPORT

List of articles citing

**A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors**

**DOI: 10.1200/jco.1990.8.6.1050**

**Journal of Clinical Oncology, 1990, 8, 1050-5.**

**Source:** <https://exaly.com/paper-pdf/21480853/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
578	Editorial Comments. <i>Journal of Urology</i> , <b>1990</b> , 144, 1127-1127	2.5	
577	Bladder cancer. <b>1990</b> , 14, 233-92		8
576	Neoadjuvant and adjuvant therapy for invasive bladder tumors. <b>1991</b> , 27, 326-30		9
575	Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer. <b>1991</b> , 27, 1383-5		18
574	M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience. <b>1991</b> , 27, 1690-4		50
573	Cisplatin combination chemotherapy for elderly patients with urothelial tumours. <b>1991</b> , 67, 603-7		16
572	CMV chemotherapy for advanced transitional cell carcinoma. <b>1992</b> , 66, 542-6		13
571	Chemotherapy for Muscle-infiltrating Bladder Cancer. <b>1992</b> , 6, 169-178		10
570	Chemotherapy for urothelial tract malignancies: breaking the deadlock. <b>1992</b> , 8, 316-41		32
569	Chemotherapy of advanced transitional-cell carcinoma of the bladder. <b>1992</b> , 30 Suppl, S99-110		9
568	Effects of cytokines on growth in vitro of primary human renal cell carcinoma. <b>1992</b> , 20, 369-73		3
567	Phase II trial of pirarubicin in the treatment of advanced bladder cancer. <b>1992</b> , 10, 317-21		6
566	Initial combination chemotherapy with cisplatin, methotrexate and vinblastine in locally advanced transitional cell carcinoma--response rate and pitfalls. MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party). <b>1992</b> , 70, 161-8		16
565	Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor. A possible new recombinant granulocyte colony-stimulating factor toxicity. <b>1992</b> , 70, 2699-702		53
564	Adjuvant chemotherapy following radical cystectomy. <b>1993</b> , 11, 169-74		2
563	Oral piritrexim, an effective treatment for metastatic urothelial cancer. <b>1993</b> , 67, 388-90		46
562	Carcinoma of the bladder. <b>1993</b> , 9, 252-66		2

561	Feasibility trial of a combination of vinorelbine, ifosfamide, fluorouracil and folinic acid (VIF regimen) in advanced urothelial cancer. <b>1993</b> , 29A, 285-6		12
560	A phase II study of cisplatin plus methotrexate with folinic acid rescue in metastatic or locally recurrent transitional cell carcinoma of the urothelium. <b>1993</b> , 29A, 347-50		12
559	Cisplatin, methotrexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium. <i>Journal of Urology</i> , <b>1993</b> , 150, 65-9	2.5	49
558	Neoadjuvant cisplatin, methotrexate and vinblastine for muscle-invasive bladder cancer: long-term followup. <i>Journal of Urology</i> , <b>1993</b> , 150, 849-52	2.5	17
557	Current management of invasive and metastatic transitional cell carcinoma of the bladder. <i>Journal of Urology</i> , <b>1993</b> , 149, 957-72	2.5	106
556	The use of nuclear morphometry in predicting recurrence of transitional cell carcinoma. <i>Journal of Urology</i> , <b>1993</b> , 149, 272-5	2.5	26
555	Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors. <b>1993</b> , 4, 403-7		34
554	The management of bladder cancer--a case history. <b>1993</b> , 4, 325-9		
553	Chemioterapia M-VAC intensificata nelle neoplasie uroteliali avanzate. <b>1994</b> , 61, 33-36		
552	Clinical and radiological aspects of infiltrating transitional cell carcinoma of the kidney. <b>1994</b> , 52, 181-4		10
551	Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial. <i>Journal of Clinical Oncology</i> , <b>1994</b> , 12, 483-8	2.2	80
550	Prognostic factors and significance of chemotherapy in patients with recurrent or metastatic transitional cell cancer of the urinary tract. <b>1994</b> , 74, 123-33		36
549	Bladder cancer: advances in biology and treatment. <b>1994</b> , 16, 33-70		7
548	P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder. <b>1994</b> , 5, 835-40		38
547	Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cis-platinum-based chemotherapy. <i>Journal of Urology</i> , <b>1994</b> , 151, 598-600; discussion 600-1	2.5	53
546	The treatment of advanced bladder cancer. <b>1995</b> , 6, 113-26		55
545	Platinum analogue combination chemotherapy: cisplatin, carboplatin, and methotrexate in patients with metastatic urothelial tract tumors. A phase II trial with evaluation of prognostic factors. <b>1995</b> , 76, 1797-803		17
544	Management of bladder cancer. <b>1995</b> , 19, 5-63		23

543	Neoadjuvant and adjuvant chemotherapy in advanced disease--what are the effects on survival and prognosis?. <b>1995</b> , 2 Suppl 2, 76-88		32
542	The design of clinical trials for new therapies in bladder cancer. Is it time for new strategies?. <b>1995</b> , 2 Suppl 2, 113-6		
541	Adjuvant Chemotherapy for Bladder Cancer. <b>1995</b> , 4, 287-294		2
540	Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. <i>Journal of Clinical Oncology</i> , <b>1995</b> , 13, 2272-7	2.2	56
539	Five-year results of neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy plus radical cystectomy in locally advanced bladder cancer. <b>1995</b> , 28, 102-7		11
538	Phase II trial of ifosfamide, fluorouracil, and folinic acid (FIFO regimen) in relapsed and refractory urothelial cancer. <b>1995</b> , 13, 276-9		4
537	Accelerated cisplatin-based chemotherapy for advanced bladder cancer. <b>1995</b> , 31A, 1633-6		6
536	Perioperative chemotherapy for invasive bladder cancer--what should we tell our patients?. <i>Journal of Urology</i> , <b>1996</b> , 155, 1246-7	2.5	3
535	Platinum-Chemotherapy for Advanced Transitional Cell Carcinoma of the Upper Urinary Tract. <b>1996</b> , 71, 945-950		8
534	Optimal delivery of perioperative chemotherapy: preliminary results of a randomized, prospective, comparative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma. <i>Journal of Urology</i> , <b>1996</b> , 155, 1241-5	2.5	40
533	Complications of radical cystectomy: impact of the timing of perioperative chemotherapy. <b>1996</b> , 47, 826-30		28
532	Chemotherapy for invasive bladder cancer. <b>1996</b> , 47, 602-14		4
531	Transitional cell carcinoma of the renal pelvis and ureter: Outcome and patterns of relapse in patients treated with postoperative radiation. <b>1996</b> , 2, 171-6		17
530	Pattern of Metastases in Relation to Characteristics of Primary Tumor and Treatment in Patients with Disseminated Urothelial Carcinoma. <i>Journal of Urology</i> , <b>1996</b> , 155, 111-114	2.5	66
529	Prolonged chemotherapy in advanced urinary cancer: Ethical considerations. <b>1996</b> , 63, 295-298		
528	Neoadjuvant CMV Chemotherapy plus Radical Cystectomy in Locally Advanced Bladder Cancer: The Impact of Pathologic Response on Long-Term Results. <b>1996</b> , 82, 463-469		5
527	Systemic Therapy for Invasive Bladder Cancer. <b>1996</b> , 3, 501-506		4
526	Platinum-Chemotherapy for Advanced Transitional Cell Carcinoma of the Upper Urinary Tract. <b>1996</b> , 71, 945-950		23

525	Systemic Chemotherapy for Advanced Bladder Carcinoma: Clinical and Experimental Results. <b>1996</b> , 27, 78-80		
524	Results of radical cystectomy and pelvic lymphadenectomy for bladder cancer with pelvic node metastases. <b>1996</b> , 57, 27-31		9
523	Bladder cancer, 1996. <b>1996</b> , 46, 93-112		54
522	Cisplatin-based chemotherapy in renal transplant recipients. A case report and a review of the literature. <b>1996</b> , 77, 160-3		17
521	Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. <b>1996</b> , 77, 344-51		124
520	A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium. <b>1996</b> , 78, 1775-80		20
519	Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy. <b>1996</b> , 74, 1655-9		43
518	Trends in clinical outcome of transitional cell carcinoma of the ureter: have the results improved?. <b>1997</b> , 58, 13-9		1
517	5-Fluorouracil, interferon-alpha-2b and cisplatin (FAP) for advanced urothelial cancer. A phase II study. Hellenic Co-operative Oncology Group. <b>1997</b> , 8, 373-8		6
516	Cisplatin, Ifosfamide, Methotrexate and Vinblastine Combination Chemotherapy for Metastatic Urothelial Cancer. <i>Journal of Urology</i> , <b>1997</b> , 158, 408-411	2.5	10
515	Current recommendations for the management of bladder cancer. Drug therapy. <b>1997</b> , 53, 404-14		20
514	Metastatic bladder cancer: advances in treatment. <b>1997</b> , 33 Suppl 1, S23-6		13
513	[Carcinomatous meningitis: rare complication of bladder cancer]. <b>1997</b> , 18, 402-6		8
512	Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. <i>Journal of Clinical Oncology</i> , <b>1997</b> , 15, 3394-8	2.2	280
511	Adjuvant and Neoadjuvant Chemotherapy for Urothelial Carcinoma. <b>1997</b> , 6, 667-681		1
510	Toxicity and results of MVAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in advanced urothelial carcinoma. <b>1997</b> , 31, 414-9		27
509	Chemotherapy with methotrexate, vinblastine, epirubicin and carboplatin (Carbo-MVE) in transitional cell urothelial cancer. A Hellenic Co-Operative Oncology Group study. <b>1997</b> , 31, 420-7		16
508	Management of invasive bladder cancer: Strategies of combined modality treatment. <b>1997</b> , 7, 37-44		

507	New approaches in the treatment of metastatic transitional-cell cancer of the bladder. <b>1997</b> , 15, 139-43	8
506	In vitro investigations of new therapeutic agents on bladder tumor cell lines. <b>1997</b> , 25, 247-50	8
505	Systemic chemotherapy of transitional cell carcinoma of the urothelium. <b>1997</b> , 13, 365-75	7
504	Vinblastine, ifosfamide, and gallium nitrate—active new regimen in patients with advanced carcinoma of the urothelium. <b>1997</b> , 79, 110-114	32
503	Paclitaxel-based second-line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (M1): a clinical Phase II study. <b>1997</b> , 80, 465-70	25
502	Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. <b>1997</b> , 80, 1966-72	171
501	Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas. <b>1998</b> , 89, 214-20	34
500	Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial. <b>1998</b> , 78, 370-4	45
499	A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party. <b>1998</b> , 78, 1067-75	71
498	Bladder cancer: state-of-the-art care. <b>1998</b> , 48, 269-84	92
497	Urge Inkontinenz beim älteren Menschen —supraspinale Reflexinkontinenz. <b>1998</b> , 38, S10-S18	5
496	[Conservative treatment of bladder cancers with radiotherapy and concurrent chemotherapy: results and perspectives]. <b>1998</b> , 2, 499-504	3
495	[Chemotherapy for urothelial infiltrating tumors]. <b>1998</b> , 2, 515-20	0
494	Chemotherapy in the elderly. <b>1998</b> , 24, 412-7	5
493	Modern concepts in the therapy of urinary tract (kidney, ureter, bladder and prostate) tumours. <b>1998</b> , 38, 151-64	1
492	ADVANCED TRANSITIONAL CELL CARCINOMA OF THE UPPER URINARY TRACT: PATTERNS OF FAILURE, SURVIVAL AND IMPACT OF POSTOPERATIVE ADJUVANT RADIOTHERAPY. <i>Journal of Urology</i> , <b>1998</b> , 160, 703-706	2.5 48
491	Welche Patienten benötigen eine adjuvante systemische Polychemotherapie nach radikaler Zystektomie?. <b>1998</b> , 38, S10-S13	
490	Cisplatin, methotrexate and mitoxantrone in patients with metastatic or advanced urothelial cancer. <b>1998</b> , 37, 110-2	2

489	Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese Urothelial Cancer Research Group. <b>1998</b> , 28, 497-501		35
488	Long abstracts. <b>1998</b> , 9, 9-60		
487	Infiltrating Bladder Cancer: Chemotherapy. <b>1998</b> , 65, 508-511		
486	Chemotherapy with methotrexate, carboplatin, mitoxantrone (Novantrone) and vincristine (Oncovin) in transitional-cell urothelial cancer. <b>1998</b> , 55, 139-44		4
485	Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group. <b>1999</b> , 10, 1385-8		53
484	Long-term follow-up results of a Pilot Phase II study of multidrug chemotherapy (MVP-CAB) in patients with advanced urothelial cancer. <b>1999</b> , 29, 204-8		2
483	A critical review of the management of bladder cancer. <b>1999</b> , 31, 193-207		6
482	Systemische Chemotherapie des Harnblasenkarzinoms. <b>1999</b> , 39, 317-320		
481	Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. <b>1999</b> , 85, 1145-50		6
480	A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium. <b>1999</b> , 86, 514-8		60
479	A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma. <b>1999</b> , 86, 1329-34		5
478	Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer. <b>1999</b> , 53, 243-50		14
477	A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carcinoma of the bladder. <i>Journal of Urology</i> , <b>1999</b> , 162, 710-4	2.5	79
476	Radiotherapy in bladder cancer. <b>1999</b> , 52, 1-14		71
475	Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. <b>1999</b> , 10, 1461-5		109
474	Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 3173-81	2.2	542
473	Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 3068-77	2.2	1562
472	Current concepts in assessment and treatment of bladder cancer. <i>Current Opinion in Urology</i> , <b>2000</b> , 10, 291-9	2.8	27

471	Advances in chemotherapy of invasive bladder cancer. <i>Current Opinion in Urology</i> , <b>2000</b> , 10, 453-7	2.8	0
470	Phase II EORTC trial with 5-fluorouracil, cisplatin and interferon-alpha as second-line treatment of advanced transitional cell cancer of the urothelial tract. <b>2000</b> , 11, 1391-4		18
469	Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract. <b>2000</b> , 88, 1671-1678		98
468	Gemcitabine in locally advanced and/or metastatic bladder cancer. <b>2000</b> , 34, 175-83		14
467	Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma. <b>2000</b> , 18, 247-51		16
466	The utility of tumour markers in assessing the response to chemotherapy in advanced bladder cancer. <b>2000</b> , 82, 1952-7		20
465	New approaches to treatment of metastatic bladder cancer. <b>2000</b> , 2, 379-85		7
464	Adjuvant and neoadjuvant chemotherapy for invasive bladder cancer. <b>2000</b> , 2, 386-93		5
463	Progress in the management of metastatic bladder cancer. <b>2000</b> , 7, 347-56		11
462	Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 3247-55	2.2	155
461	Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 840-6	2.2	55
460	Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 1921-7	2.2	192
459	Second-line chemotherapy in advanced bladder cancer. <b>2000</b> , 64, 61-9		6
458	Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial. <b>2000</b> , 36, 74-9		20
457	The functional and psychosocial status of patients with disseminated bladder cancer. <b>2000</b> , 5, 20-4		4
456	Advanced bladder and urothelial cancers. <b>2000</b> , 36 Suppl 2, 1-6		9
455	Paclitaxel and carboplatin in bladder cancer: recent developments. <b>2000</b> , 36 Suppl 2, 7-12		25
454	Exploring sequenced chemotherapy regimens in the treatment of transitional cell carcinoma of the urothelial tract. <b>2000</b> , 36 Suppl 2, 26-9		7



453	Gemcitabine and paclitaxel combination therapy in transitional cell carcinoma of the urothelium. <b>2000</b> , 36 Suppl 2, 30-3		5
452	Gemcitabine and cisplatin in locally advanced and/or metastatic bladder cancer. <b>2000</b> , 36 Suppl 2, 13-6		15
451	Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer. <b>2000</b> , 36 Suppl 2, 17-25		11
450	Evaluation of drug delivery and survival impact of dose-intense relative to conventional-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in urothelial cancer. <b>2000</b> , 18, 626-34		6
449	Gemcitabine in the treatment of bladder cancer. <b>2000</b> , 1, 547-53		2
448	THE EFFECT OF CYSTECTOMY, AND PERIOPERATIVE METHOTREXATE, VINBLASTINE, DOXORUBICIN AND CISPLATIN CHEMOTHERAPY ON THE RISK AND PATTERN OF RELAPSE IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER. <i>Journal of Urology</i> , <b>2000</b> , 163, 1413-1418	2.5	22
447	GEMCITABINE PLUS CISPLATIN FOR ADVANCED TRANSITIONAL CELL CARCINOMA OF THE URINARY TRACT: A PHASE II MULTICENTER TRIAL. <i>Journal of Urology</i> , <b>2000</b> , 164, 53-56	2.5	39
446	PHASE II STUDY OF PACLITAXEL AND CISPLATIN FOR ADVANCED UROTHELIAL CANCER. <i>Journal of Urology</i> , <b>2000</b> , 164, 1538-1542	2.5	50
445	Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study. <i>Journal of Urology</i> , <b>2001</b> , 165, 67-71	2.5	85
444	Adjuvant therapy of melanoma: at what cost?. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 1226-8	2.2	3
443	Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 2527-33	2.2	166
442	Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 1021-9	2.2	49
441	Secondary leukemia after adjuvant chemotherapy for breast cancer. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 1231-3	2.2	4
440	Gemcitabine and cisplatin for advanced, metastatic bladder cancer. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 1229-31	2.2	27
439	Staging of breast cancer: it is time to break with tradition and initiate the evidence-based-medicine age. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 1234	2.2	6
438	Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 1233-4	2.2	4
437	Neoadjuvant MVAC: the long and winding road is getting shorter and straighter. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 4003-4	2.2	2
436	Subclassification of N2 non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 1228	2.2	

435	Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 3018-24	2.2	160
434	Second-line treatment of advanced transitional cell carcinoma of the urothelial tract. <i>Current Opinion in Urology</i> , <b>2001</b> , 11, 523-9	2.8	11
433	Recent advances in bladder cancer chemotherapy. <b>2001</b> , 19, 77-85		13
432	Metastatic urothelial cancer: evaluation of prognostic factors and change in prognosis during the last twenty years. <b>2001</b> , 39, 634-42		27
431	Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 2638-46	2.2	465
430	Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features. <b>2001</b> , 12, 947-52		47
429	Transitional cell carcinoma of the bladder: new approaches to the treatment of advanced disease. <b>2001</b> , 3, 285-6		
428	Chemotherapy and management of bladder tumours. <b>2000</b> , 85, 599-610		24
427	A standardization method to adjust for the effect of patient selection in phase II clinical trials. <b>2001</b> , 20, 883-92		15
426	Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. <b>2001</b> , 92, 2993-8		178
425	Gemcitabine-Containing Regimens in Bladder Cancer: A New Standard of Care. <b>2001</b> , 28, 1-3		3
424	Gemcitabine/Carboplatin in Advanced Urothelial Cancer. <b>2001</b> , 28, 19-24		7
423	Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial. <b>2002</b> , 13, 243-50		43
422	Neoadjuvant chemotherapy with sequential methotrexate and 5-fluorouracil scheduling, epirubicin and cisplatin for locally advanced bladder cancer. <b>2002</b> , 63, 1-5		2
421	Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours. <b>2002</b> , 41, 447-56		62
420	High-risk metastatic urothelial cancer: chances for cure?. <i>Current Opinion in Urology</i> , <b>2002</b> , 12, 441-8	2.8	19
419	Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer. <b>2002</b> , 20, 673-85		31
418	Hematoporphyrin-derived soluble porphyrin-platinum conjugates with combined cytotoxic and phototoxic antitumor activity. <b>2002</b> , 45, 2064-78		97

417	Chemotherapy in Metastatic Urothelial Cancer. <b>2002</b> , 1, 23-31		
416	Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. <b>2002</b> , 7, 153-7		48
415	Pilot study of sequentially applied doublets in poor-prognosis metastatic urothelial cancer. <b>2002</b> , 7, 235-7		1
414	The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. <b>2002</b> , 3, 738-47		51
413	Tratamiento de los tumores epiteliales de la vejiga. <b>2002</b> , 34, 1-13		
412	Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 937-40	2.2	187
411	Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 1361-7	2.2	61
410	Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer. <b>2002</b> , 29, 36-9		9
409	Current and future perspectives in advanced bladder cancer: is there a new standard?. <b>2002</b> , 29, 3-14		25
408	Gemcitabine doublets in advanced urothelial cancer. <b>2002</b> , 29, 15-9		12
407	The present and future of combination chemotherapy in bladder cancer. <b>2002</b> , 29, 32-9		55
406	Guidelines on bladder cancer. <b>2002</b> , 41, 105-12		302
405	Surgery and adjunctive chemotherapy for invasive bladder cancer. <b>2002</b> , 11, 55-63		30
404	Follow-up surveillance strategies for genitourinary malignancies. <b>2002</b> , 94, 2892-905		13
403	Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens. <b>2002</b> , 95, 1444-50		34
402	Chemotherapy in the post-MVAC era: the case for adjuvant chemotherapy. <b>2002</b> , 20, 144-50		13
401	New drugs and new approaches for the treatment of metastatic urothelial cancer. <b>2002</b> , 20, 158-66		30
400	The role of chemotherapy and radiation in organ-preservation strategies for muscle-invasive bladder cancer. <b>2002</b> , 20, 167-74		3

399	Neo-adjuvant treatment of infiltrating transitional-cell carcinoma of the bladder with paclitaxel and cisplatin: a phase II trial. <b>2002</b> , 9, 162-6	6
398	The efficacy of neoadjuvant chemotherapy in invasive bladder cancer. <b>2002</b> , 33, 49-52	7
397	[Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany]. <b>2003</b> , 42, 1074-86	5
396	Progress in the chemotherapy of metastatic cancer of the urinary tract. <b>2003</b> , 97, 2050-5	21
395	Molecular targeting and pharmacogenomics in the management of advanced bladder cancer. <b>2003</b> , 97, 2083-9	35
394	Southwest Oncology Group studies in bladder cancer. <b>2003</b> , 97, 2099-108	7
393	Overview of bladder cancer trials in the European Organization for Research and Treatment. <b>2003</b> , 97, 2120-6	41
392	Overview of gemcitabine triplets in metastatic bladder cancer. <b>2003</b> , 45, 191-7	8
391	Therapeutic approaches to bladder cancer: identifying targets and mechanisms. <b>2003</b> , 46 Suppl, S67-83	40
390	Is there standard chemotherapy for metastatic bladder cancer? Quality of life and medical resources utilization based on largest to date randomized trial. <b>2003</b> , 47, 171-9	9
389	New drugs and new approaches in metastatic bladder cancer. <b>2003</b> , 47, 195-206	25
388	Advanced ureteral cancer with complete remission achieved by taxan containing systemic chemotherapy. <b>2003</b> , 10, 105-7	1
387	[Advanced bladder cancer: new therapeutic strategies]. <b>2003</b> , 120, 68-77	
386	Optimal administration schedule of cisplatin for bladder tumor with minimal induction of metallothionein. <i>Journal of Urology</i> , <b>2003</b> , 170, 2467-70	2.5 6
385	Phase II trial of cisplatin, 5-fluorouracil, and interferon-alpha-2B as first line treatment of advanced urothelial cancer. <b>2003</b> , 21, 185-9	2
384	Chemotherapy and cystectomy for invasive transitional cell carcinoma of bladder. <b>2003</b> , 21, 468-74	25
383	The systemic treatment of advanced and metastatic bladder cancer. <b>2003</b> , 4, 489-97	88
382	Metastatic Bladder Cancer: Role of Chemotherapy and New Agents. <b>2003</b> , 1, 108-117	5

381	Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. <b>2003</b> , 349, 859-66		1772
380	Abstract. <b>2003</b> , 21, 1-108		24
379	Cancer of the Bladder. 346-353		
378	[Systemic chemotherapy for transitional cell carcinoma of the urothelium]. <b>2003</b> , 26 Suppl 4, 18-25		1
377	Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Regimen for Urothelial Tract Tumors. <b>2004</b> , 39, 836-852		
376	Treatment of invasive bladder cancer: lessons from the past and perspective for the future. <b>2004</b> , 34, 295-306		17
375	Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 220-8	2.2	147
374	Interventional Radiology in Cancer. <i>Medical Radiology</i> , <b>2004</b> ,	0.2	1
373	A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. <b>2004</b> , 91, 844-9		78
372	Long-term Outcome of Adjuvant Chemotherapy with MVP-CAB Regimen (Methotrexate, Vincristine, Cisplatin, Cyclophosphamide, Adriamycin and Bleomycin) for Locally Advanced Bladder Cancer. <b>2004</b> , 4, 151-156		1
371	A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer. <b>2004</b> , 22, 374-82		16
370	The phase III candidate: can we improve the science of selection?. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 211-3	2.2	28
369	The role of the nonsurgical oncologist in the management of advanced transitional cell cancer. Part II: metastatic disease. <b>2004</b> , 94, 981-4		1
368	Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. <b>2004</b> , 100, 1639-45		141
367	Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement. <b>2004</b> , 101, 1803-8		22
366	Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. <i>Journal of Urology</i> , <b>2004</b> , 171, 145-8	2.5	109
365	Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. <i>Journal of Urology</i> , <b>2004</b> , 171, 561-9	2.5	276
364	Systemic chemotherapy for patients with bladder cancer--current controversies and future directions. <b>2004</b> , 30, 343-58		39

363	Tyrosine kinase inhibitors of the epidermal growth factor receptor as adjuncts to systemic chemotherapy for muscle-invasive bladder cancer. <b>2004</b> , 63, 619-24		17
362	Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. <b>2004</b> , 64, 479-84		97
361	Retroperitoneal lymph node dissection in patients with interaortocaval lymph node metastases of transitional cell carcinoma of the urinary tract. <b>2004</b> , 11, 243-7		4
360	Chemotherapy in Locally Advanced and Metastatic Bladder Cancer. <b>2004</b> , 3, 79-88		
359	Recent developments in advanced urothelial cancer. <i>Current Opinion in Urology</i> , <b>2005</b> , 15, 342-9	2.8	5
358	A nonplatinum combination in metastatic transitional cell carcinoma. <b>2005</b> , 28, 114-8		7
357	Is the use of anything but MVAC justified in the evidence-based medicine era?. <i>Current Opinion in Urology</i> , <b>2005</b> , 15, 312-4	2.8	1
356	Methotrexate-Paclitaxel-Epirubicin-Carboplatin (M-TEC) Combination Chemotherapy in Patients with Advanced Bladder Cancer: An Open Label Phase II Study. <b>2005</b> , 17, 444-448		7
355	Chemotherapy for metastatic bladder cancer. <b>2005</b> , 17, 514-23		6
354	Phase II trial of weekly paclitaxel and carboplatin chemotherapy in patients with advanced transitional cell cancer. <b>2005</b> , 48, 246-51		6
353	Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium. <b>2005</b> , 103, 2298-303		48
352	Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study. <b>2005</b> , 104, 1627-32		48
351	Systemische Therapie des fortgeschrittenen Urothelkarzinoms. <b>2005</b> , 11, 1210-1218		
350	Adjuvant chemotherapy for transitional cell carcinoma of the bladder: paradigms for the design of clinical trials. <b>2005</b> , 7, 207-14		2
349	Chemotherapy for Bladder Cancer. <b>2005</b> , 145-155		
348	Toxicity of the topoisomerase II inhibitors. <b>2005</b> , 4, 219-34		79
347	Principles of Chemotherapy for Genitourinary Cancer. <b>2005</b> , 51-87		
346	Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 4963-74	2.2	74

345	Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 1185-91	2.2	81
344	Bladder cancer "adjuvant-lite": tastes great (works as well) and less filling (less toxic)?. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 4823-6	2.2	6
343	Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report. <b>2005</b> , 35, 79-83		7
342	Systemic chemotherapy for patients with advanced and metastatic bladder cancer: current status and future directions. <b>2005</b> , 16 Suppl 4, iv85-89		13
341	The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy. <b>2005</b> , 32, 217-30, vii		6
340	Neoadjuvant chemotherapy in patients with invasive bladder cancer. <b>2005</b> , 32, 231-7		14
339	Pemetrexed: a multitargeted antifolate. <b>2005</b> , 27, 1343-82		91
338	The management of lymph node metastasis from bladder cancer. <b>2005</b> , 31, 348-56		11
337	Update on chemotherapy for advanced bladder cancer. <i>Journal of Urology</i> , <b>2005</b> , 174, 14-20	2.5	115
336	Neoadjuvant Chemotherapy in Bladder Cancer. <b>2005</b> , 4, 71-75		
335	Chemotherapy in Locally Advanced and Metastatic Bladder Cancer. <b>2005</b> , 4, 1-13		3
334	Chemotherapy practices and perspectives in invasive bladder cancer. <b>2006</b> , 6, 1473-82		2
333	Nonplatinum therapy in advanced bladder cancer. <b>2006</b> , 6, 887-94		4
332	Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. <i>Journal of Urology</i> , <b>2006</b> , 175, 1262-7; discussion 1267	2.5	139
331	Systemic chemotherapy in locally advanced and/or metastatic bladder cancer. <b>2006</b> , 32, 456-70		26
330	Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. <b>2006</b> , 42, 50-4		363
329	Systemic Therapy for Bladder Cancer. 188-211		
328	Importance of node dissection in relation to neoadjuvant and adjuvant therapy. <b>2006</b> , 4, 1019-26		1

327 . 2006,

- 326 Gemcitabine and cisplatin after radical cystectomy for bladder cancer in an adjuvant setting: feasibility study from the Genito-Urinary Group of the French Federation of Cancer Centers. **2006**, 17, 705-8 6
- 325 Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer. **2006**, 97, 42-7 97
- 324 EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. **2006**, 25, 769-80 76
- 323 Perioperative chemotherapy for bladder cancer. **2006**, 57, 133-44 17
- 322 From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. **2006**, 24, 37-77 127
- 321 State-of-the-art management of metastatic disease at initial presentation or recurrence. **2006**, 24, 543-56 13
- 320 Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy. **2006**, 58, 402-7 21
- 319 Feasibility study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function. **2006**, 8, 755-7 18
- 318 Systemic chemotherapy for urothelial cancer. **2006**, 5, 34-42 1
- 317 Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer. **2006**, 5, 150-4 12
- 316 The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group. **2006**, 106, 297-303 63
- 315 Adjuvant chemotherapy in muscle-invasive bladder carcinoma: a pooled analysis from phase III studies. **2006**, 106, 783-8 69
- 314 Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity. **2006**, 106, 1269-75 22
- 313 Phase I/II study of a combined gemcitabine, etoposide, and cisplatin chemotherapy regimen for metastatic urothelial carcinoma. **2006**, 106, 2363-8 9
- 312 Developing innovative strategies for advanced transitional cell carcinoma of the bladder. **2006**, 6, 83-92 1
- 311 Combining surgery and chemotherapy for invasive bladder cancer: current and future directions. **2006**, 6, 281-91 7
- 310 Adjuvant chemotherapy of bladder cancer. **2006**, 17 Suppl 5, v129-32 11



309	Muscle invasive and metastatic bladder cancer. <b>2006</b> , 17 Suppl 10, x23-30		13
308	Neo-adjuvant chemotherapy for muscle-invasive bladder cancer: a look ahead. <b>2006</b> , 17, 1360-9		8
307	Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium. <b>2006</b> , 17 Suppl 5, v113-7		16
306	The role of perioperative chemotherapy in the treatment of urothelial cancer. <b>2006</b> , 11, 630-40		12
305	Systemic chemotherapy options for metastatic bladder cancer. <b>2006</b> , 6, 877-85		8
304	Systemic chemotherapy for advanced bladder cancer: update and controversies. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 5545-51	2.2	60
303	Systemic chemotherapy in inoperable or metastatic bladder cancer. <b>2006</b> , 17, 553-61		34
302	Is gemcitabine cost effective in cancer treatment?. <b>2007</b> , 7, 239-49		1
301	Therapy of metastatic bladder carcinoma. <b>2007</b> , 18 Suppl 6, vi153-6		10
300	Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: report of efficacy, quality of life and geriatric assessment. <b>2007</b> , 73, 290-7		41
299	Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. <b>2007</b> , 18, 1359-62		46
298	The evolving role of chemotherapy in advanced urothelial cancer. <b>2007</b> , 1, 180-6		1
297	Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. <b>2007</b> , 69, 62-79		144
296	Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy. <b>2007</b> , 69, 390-4		47
295	Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens. <b>2007</b> , 69, 479-84		22
294	Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract. <b>2007</b> , 9, 18-22		28
293	Harnblasenkarzinom. <b>2007</b> , 301-372		
292	Where are we with the treatment of metastatic bladder cancer?. <b>2007</b> , 16, 1311-4		2

291	New agents for treatment of advanced transitional cell carcinoma. <b>2007</b> , 18, 835-43	21
290	Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma. <i>Journal of Urology</i> , <b>2007</b> , 177, 84-9; discussion 89	2.5 24
289	Five-year, disease-free survival after repeat palliative multimodality therapy in a patient with recurrent metastatic bladder cancer. <b>2007</b> , 7, 1736-42	
288	Multidisciplinary Management of Genitourinary Malignancies. <b>2007</b> ,	
287	Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma. <b>2007</b> , 14, 1000-4; discussion 1004	27
286	Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. <b>2007</b> , 52, 134-41	211
285	Impact of multimodal treatment on survival in patients with metastatic urothelial cancer. <b>2007</b> , 52, 1106-13	56
284	The atypical urothelial cancer patient: management of bladder cancers of non-transitional cell histology and cancers of the ureters and renal pelvis. <b>2007</b> , 34, 145-53	14
283	Chemotherapy for metastatic or unresectable bladder cancer. <b>2007</b> , 34, 135-44	20
282	[Therapy and follow-up of bladder cancer]. <b>2007</b> , 157, 162-9	1
281	Konventionelle und experimentelle Systemtherapie des fortgeschrittenen Urothelkarzinoms. <b>2007</b> , 13, 1109-1120	
280	Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy. <b>2008</b> , 13, 510-4	47
279	Advanced bladder cancer: so many drugs, so little progress : what's wrong with this picture?. <b>2008</b> , 113, 1275-7	4
278	Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting. <b>2008</b> , 113, 1284-93	56
277	Systemic therapy for metastatic urothelial carcinoma. <b>2008</b> , 101, 795-803	4
276	Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer. <b>2008</b> , 102, 1339-44	17
275	Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy. <b>2008</b> , 6, 31-5	10
274	Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy. <b>2008</b> , 6, 36-9	23

273	[Metastases from urethelial carcinoma: role of chemotherapy]. <b>2008</b> , 18 Suppl 7, S261-76		1
272	Neoadjuvant chemotherapy preceding cystectomy for bladder cancer. <b>2008</b> , 9, 1885-93		2
271	Urological Oncology. <b>2008</b> ,		2
270	Current optimal chemotherapy for advanced urothelial cancer. <b>2008</b> , 8, 51-61		5
269	Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer. <b>2009</b> , 9, 821-30		18
268	A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma. <b>2009</b> , 55, 321-6		13
267	Management of patients with advanced bladder cancer following major response to systemic chemotherapy. <b>2009</b> , 9, 1757-64		7
266	Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4062-7	2.2	36
265	Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. <b>2009</b> , 55, 177-85		174
264	Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). <b>2009</b> , 55, 1293-9		89
263	The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. <b>2009</b> , 55, 815-25		260
262	Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series. <b>2009</b> , 115, 792-9		75
261	Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000. <b>2009</b> , 115, 1435-47		57
260	A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. <b>2009</b> , 115, 2881-90		175
259	Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract. <b>2009</b> , 26, 186-92		25
258	Bladder cancer. <b>2009</b> , 10, 205-15		27
257	[Complete resection of urothelial cancer metastases with curative intent]. <b>2009</b> , 48, 143-50		1
256	Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents. <b>2009</b> , 69, 211-22		42

255	Management of bladder cancer: current and emerging strategies. <b>2009</b> , 69, 1173-87		12
254	Harnblasenkarzinom. <b>2009</b> , 395-476		0
253	Development of novel agents for bladder cancer. <b>2009</b> , 3, 160-169		
252	Treatment Decisions for Advanced Genitourinary Cancers: From Symptoms to Risk Assessment. <b>2009</b> , 8, 738-746		4
251	Oncological followup after radical cystectomy for bladder cancer-is there any benefit?. <i>Journal of Urology</i> , <b>2009</b> , 181, 1587-93; discussion 1593	2.5	86
250	[Treatment strategies for metastatic patients in bladder cancer]. <b>2010</b> , 97 Suppl Cancer de la vessie, 27-33		0
249	Bladder cancer: current management and opportunities for a personalized approach. <b>2010</b> , 77, 587-96		8
248	Bladder cancer: can we move beyond chemotherapy?. <b>2010</b> , 12, 278-83		6
247	Actualizaci3n de las Gu3as Cl3nicas de la Asociaci3n Europea de Urolog3a sobre el carcinoma vesical m3sculo-invasivo y metast3tico. <b>2010</b> , 34, 51-62		9
246	Gemcitabine and carboplatin in the treatment of transitional cell carcinoma of the urothelium: a single centre experience and review of the literature. <b>2010</b> , 19, 324-8		12
245	Management of renal and bladder cancer in older adults. 171-185		
244	Choosing chemotherapy in patients with advanced urothelial cell cancer who are unfit to receive cisplatin-based chemotherapy. <b>2010</b> , 2, 381-8		8
243	Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise. <b>2010</b> , 19, 875-87		19
242	Update of the Clinical Guidelines of the European Association of Urology on muscle-invasive and metastatic bladder carcinoma. <b>2010</b> , 34, 51-62		2
241	Integrating antiangiogenic therapy for advanced urothelial carcinoma: rationale for a phase II study of gemcitabine, cisplatin, and sunitinib. <b>2010</b> , 7, 500-504		1
240	Bladder Cancer. <b>2010</b> ,		1
239	MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. <b>2010</b> , 12, 628-36		106
238	Gemcitabine for unresectable, locally advanced or metastatic bladder cancer. <b>2011</b> , CD008976		5

237	Current treatment of metastatic bladder cancer and future directions. <b>2011</b> , 11, 1851-62	21
236	[The role of chemotherapy in the management of bladder cancer]. <b>2011</b> , 21, 369-82	4
235	[New concepts in the management of MIBC in 2010]. <b>2011</b> , 21 Suppl 2, S38-42	2
234	Management of advanced bladder cancer in patients with impaired renal function. <b>2011</b> , 11, 931-9	6
233	Gemcitabine for unresectable, locally advanced or metastatic bladder cancer. <b>2011</b> ,	4
232	Carboplatin and gemcitabine in patients with advanced and/or metastatic urothelial cancers: A phase II study. <b>2011</b> , 2, 31-35	2
231	First- and second-line therapy for metastatic urothelial carcinoma of the bladder. <b>2011</b> , 18, e25-34	60
230	Current therapeutic strategies for invasive and metastatic bladder cancer. <b>2011</b> , 4, 97-113	28
229	Update on chemotherapy in the treatment of urothelial carcinoma. <b>2011</b> , 11, 1981-94	21
228	Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urothelium unfit for cisplatin-based chemotherapy: a randomized phase 2 study of the French Genitourinary Tumor Group (GETUG V01). <b>2011</b> , 60, 1251-7	24
227	Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma. <b>2011</b> , 16, 533-8	4
226	Weekly regimen of epirubicin and paclitaxel as second-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study. <b>2011</b> , 28 Suppl 1, S426-32	10
225	SEOM clinical guidelines for the treatment of invasive bladder cancer. <b>2011</b> , 13, 552-9	5
224	Current management of muscle-invasive bladder cancer. <b>2011</b> , 13, 855-61	2
223	Neoadjuvant or adjuvant chemotherapy: what is the best treatment of muscle invasive bladder cancer?. <b>2011</b> , 5, 185-189	1
222	Chemotherapy in advanced bladder cancer: current status and future. <b>2011</b> , 4, 35	47
221	Hypomethylating agents for urologic cancers. <b>2011</b> , 7, 447-63	5
220	A pure microcytic bladder carcinoma synchronous to prostatic adenocarcinoma. <b>2011</b> , 3, e30	

219	Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1107-13	2.2	323
218	Metastatic bladder cancer: anything new?. <b>2012</b> , 6, 304-9		7
217	Value of current chemotherapy and surgery in advanced and metastatic bladder cancer. <b>2012</b> , 88, 249-58		64
216	Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum. <b>2012</b> , 30, 1984-90		51
215	Retrospective analysis of survival in muscle-invasive bladder cancer: impact of pT classification, node status, lymphovascular invasion, and neoadjuvant chemotherapy. <b>2012</b> , 461, 467-74		8
214	Newer developments in the therapeutics of the transitional cell carcinoma of renal pelvis. <b>2012</b> , 18, 97-103		4
213	Blasenkrebs [Aktuelles zu Biologie, Diagnostik und Therapie. <b>2012</b> , 62, 10-20		1
212	Recommendations for the optimal management of early and advanced urothelial carcinoma. <b>2012</b> , 38, 431-41		10
211	Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen. <b>2012</b> , 48, 1141-6		18
210	A phase II trial of temsirolimus in second-line metastatic urothelial cancer. <b>2012</b> , 29, 2870-6		36
209	New therapeutic challenges in advanced bladder cancer. <b>2012</b> , 39, 598-607		75
208	Bladder Cancer and Upper Tracts. <b>2012</b> , 311-333		
207	Sequential therapy with gemcitabine and Carboplatin followed by Paclitaxel as first line treatment for advanced urothelial cancer. <b>2012</b> , 3, 362-8		3
206	Current chemotherapeutic strategies against bladder cancer. <b>2012</b> , 44, 431-41		6
205	Neoadjuvant and adjuvant chemotherapy for locally advanced bladder carcinoma: development of novel bladder preservation approach, Osaka Medical College regimen. <b>2012</b> , 19, 26-38		5
204	Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. <b>2012</b> , 109, 846-54		82
203	Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin. <b>2012</b> , 110, 1478-84		25
202	A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder. <b>2013</b> , 72, 263-7		6

201	Combination of gemcitabine and carboplatin as first line treatment in elderly patients or those unfit for cisplatin-based chemotherapy with advanced transitional cell carcinoma of the urinary tract. <b>2013</b> , 71, 1033-9	14
200	Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma. <b>2013</b> , 11, 316-20	4
199	A phase II study of mitomycin, fluorouracil, folinic acid, and irinotecan (MFI) for the treatment of transitional cell carcinoma of the bladder. <b>2013</b> , 31, 878-82	4
198	Advanced bladder cancer: new agents and new approaches. A review. <b>2013</b> , 31, 9-16	10
197	Neoadjuvant chemotherapy in muscle-invasive bladder cancer: ready for prime time?. <b>2013</b> , 85, 288-94	4
196	Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. <b>2013</b> , 11, 175-81	74
195	Could salvage surgery after chemotherapy have clinical impact on cancer survival of patients with metastatic urothelial carcinoma?. <b>2013</b> , 18, 110-5	9
194	A Smac mimetic augments the response of urothelial cancer cells to gemcitabine and cisplatin. <b>2013</b> , 14, 812-22	15
193	Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. <b>2013</b> , 105, 499-503	63
192	Second-line systemic therapy for metastatic urothelial carcinoma of the bladder. <b>2013</b> , 9, 1637-51	14
191	Role of systemic chemotherapy in urothelial urinary bladder cancer. <b>2013</b> , 20, 200-10	20
190	Optimizing systemic therapy for bladder cancer. <b>2013</b> , 11, 793-804	21
189	Why consider neoadjuvant chemotherapy for muscle-invasive transitional cell carcinoma of the bladder?. <b>2008</b> , 2, 222-4	5
188	Systemische Therapie des metastasierten Urothelkarzinoms. <b>2014</b> , 20, 1133-1135	
187	Salvage therapy for recurrence of bladder cancer: do we need a uniform approach?. <b>2014</b> , 7, 397-9	
186	Cisplatin resistance by induction of aldo-keto reductase family 1 member C2 in human bladder cancer cells. <b>2014</b> , 7, 674-678	16
185	Sunitinib malate in the treatment of urothelial cancer. <b>2014</b> , 23, 115-24	3
184	Serum total hCG level is an independent prognostic factor in transitional cell carcinoma of the urothelial tract. <b>2014</b> , 110, 1759-66	20

183	Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage. <b>2014</b> , 25, 878-86	12
182	A phase II study of gemcitabine and irinotecan in patients with locally advanced or metastatic bladder cancer. <b>2014</b> , 37, 188-93	5
181	Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer. <b>2014</b> , 12, 71-3	34
180	Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer. <b>2014</b> , 12, 203-209.e1	14
179	Gemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinoma. <b>2014</b> , 19, 516-22	14
178	Chemotherapeutic and targeted biological agents for metastatic bladder cancer: a comprehensive review. <b>2014</b> , 21, 630-7	22
177	Multimodal management of muscle-invasive bladder cancer. <b>2014</b> , 38, 80-108	45
176	Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma. <b>2014</b> , 32, 35.e1-7	2
175	Synergistic antitumor effect of ginsenoside Rg3 and cisplatin in cisplatin-resistant bladder tumor cell line. <b>2014</b> , 32, 1803-8	31
174	Emerging immunotherapies for bladder cancer. <b>2015</b> , 27, 191-200	21
173	The Role of Population-Based Observational Research in Bladder Cancer. <b>2015</b> , 1, 123-131	1
172	Pharmacokinetic and toxicity considerations in the use of neoadjuvant chemotherapy for bladder cancer. <b>2015</b> , 11, 731-42	9
171	Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy. <b>2015</b> , 13, 178-84	12
170	Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma. <b>2015</b> , 41, 699-706	12
169	Cytotoxic and DNA-targeted therapy in urothelial cancer: have we squeezed the lemon enough?. <b>2015</b> , 121, 179-87	11
168	First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patients. <b>2015</b> , 29, 319-28, ix-x	19
167	Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?. <b>2015</b> , 11, 107-19	11
166	Role of neoadjuvant chemotherapy in muscle-invasive bladder cancer: Clinical and cost effectiveness. <b>2015</b> , 8, 279-284	1



165	Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?. <b>2015</b> , 11, 2299-306	18
164	Management of Bladder Cancer. <b>2015</b> ,	1
163	Upper Tract Urothelial Carcinoma. <b>2015</b> ,	
162	Early prediction of cisplatin-induced nephrotoxicity by urinary vanin-1 in patients with urothelial carcinoma. <b>2016</b> , 359-360, 71-5	22
161	Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma. <b>2016</b> , 14, 494-498	1
160	Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. <b>2016</b> , 17, 1590-1598	45 <sup>o</sup>
159	Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope. <b>2016</b> , 50, 208-216	11
158	Use of Palliative Chemotherapy for Advanced Bladder Cancer: Patterns of Care in Routine Clinical Practice. <b>2016</b> , 14, 291-8	2
157	Chemotherapy for Muscle-Invasive Bladder Cancer. <b>2016</b> , 17, 6	8
156	Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma. <b>2016</b> , 14, e75-9	54
155	Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. <b>2016</b> , 69, 634-641	47
154	Contemporary update on neoadjuvant therapy for bladder cancer. <b>2017</b> , 14, 348-358	18
153	Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer. <b>2017</b> , 92, 1564-1582	18
152	Systematic Review of Immune Checkpoint Inhibition in Urological Cancers. <b>2017</b> , 72, 411-423	61
151	Urothelial Tumors. <b>2017</b> , 59-93	
150	Recent progress with next-generation biomarkers in muscle-invasive bladder cancer. <b>2017</b> , 24, 7-15	10
149	Oncologic Imaging: Urology. <b>2017</b> ,	2
148	Systemic, perioperative management of muscle-invasive bladder cancer and future horizons. <b>2017</b> , 14, 221-234	66

147	Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review. <b>2017</b> ,		1
146	Systemic chemotherapy in muscle invasive and metastatic bladder cancer: present and future. <b>2017</b> , 84, 130-141		7
145	Immune Checkpoint Blockade in Metastatic Urothelial Cancer. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2109-2112	2.2	9
144	Role of Radical Cystectomy in Non-Organ Confined Bladder Cancer: A Systematic Review. <b>2018</b> , 4, 31-40		8
143	SATB1 and bladder cancer: Is there a functional link?. <b>2018</b> , 36, 93.e13-93.e21		6
142	Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition. <b>2018</b> , 15, 112-124		52
141	Systemic Therapy for Advanced Urothelial Carcinoma: Current Standards and Treatment Considerations. <b>2018</b> , 38, 342-353		6
140	Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions. <b>2018</b> , 19, 109		32
139	The continuing role of chemotherapy in the management of advanced urothelial cancer. <b>2018</b> , 10, 455-480		11
138	Impact of Neoadjuvant Chemotherapy on Pathologic Response in Patients With Upper Tract Urothelial Carcinoma Undergoing Extirpative Surgery. <b>2018</b> , 16, e1237-e1242		24
137	Section VI. Chemotherapy for Metastatic Bladder Cancer. <b>2018</b> , 523-537		
136	Comparison of efficacy and toxicity of second-line combination chemotherapy regimens in patients with advanced urothelial carcinoma. <b>2018</b> , 23, 944-950		6
135	6 - Terapia Trimodale Nel Trattamento Conservativo Della Neoplasia Vescicale. <b>2018</b> , 104, S23-S27		
134	Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review. <b>2018</b> , 7, CD012838		4
133	Metastatic bladder cancer. <b>2018</b> , 383-389		
132	A Gene Expression Signature Predicts Bladder Cancer Cell Line Sensitivity to EGFR Inhibition. <b>2018</b> , 4, 269-282		4
131	Urothelial carcinoma: the evolving landscape of immunotherapy for patients with advanced disease. <b>2018</b> , 10, 7-16		20
130	A Complex Cardiac Mass Originating from Interatrial Septum in a Patient with History of Kidney Cancer: A Case Report and Literature Review. <b>2018</b> , 2018, 1764057		

129	Second-Line Systemic Treatment for Metastatic Urothelial Carcinoma: A Network Meta-Analysis of Randomized Phase Clinical Trials. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 679	5.3	2
128	[50 years of systemic therapy of urinary bladder cancer]. <b>2019</b> , 50, 358-365		2
127	Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers. <b>2019</b> , 144, 102812		5
126	Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter. <b>2019</b> , 11, 1756287218815372		6
125	Immunotherapy for genitourinary tumors. <b>2019</b> , 26, 326-333		6
124	The role of metastatic burden in cytoreductive/consolidative radical cystectomy. <b>2019</b> , 37, 2691-2698		5
123	Management of metastatic bladder cancer. <b>2019</b> , 76, 10-21		104
122	Which treatment is best for patients with AJCC stage IV bladder cancer?. <b>2019</b> , 51, 1145-1156		5
121	Beyond first-line systemic treatment for metastatic urothelial carcinoma of the bladder. <b>2019</b> , 21, 280-288		2
120	Treatment of Metastatic Bladder Cancer. <b>2019</b> , 123-137		
119	Management of Urothelial Carcinoma. <b>2019</b> ,		
118	Recurrent oligometastatic transitional cell bladder carcinoma: is there room for radiotherapy?. <b>2019</b> , 66, 160-165		7
117	Carcinoma of the Bladder. <b>2020</b> , 1382-1400.e4		0
116	Review: Brain Metastases in Bladder Cancer. <b>2020</b> , 6, 237-248		1
115	Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options. <b>2020</b> , 89, 102072		6
114	Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer. <b>2020</b> , 11, 575258		14
113	Efficacy and Safety of Chemotherapy Regimens in Advanced or Metastatic Bladder and Urothelial Carcinomas: An Updated Network Meta-Analysis. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 1507	5.6	2
112	Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers. <b>2020</b> , 154, 102891		1

111	Muscle Invasive Bladder Cancer and Neoadjuvant Chemotherapy. <b>2021</b> , 189-196		
110	Cytotoxic Chemotherapy for Advanced Bladder and Upper Tract Cancer. <b>2021</b> , 289-304		
109	Immune Checkpoints Inhibitors and Chemotherapy as First-Line Treatment for Metastatic Urothelial Carcinoma: A Network Meta-Analysis of Randomized Phase III Clinical Trials. <b>2021</b> , 13,		3
108	Paradigms on Immunotherapy Combinations with Chemotherapy. <b>2021</b> , 11, 1353-1367		43
107	Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy Regimens. <b>2021</b> , 19, 125-134		1
106	Current Therapy for Metastatic Urothelial Carcinoma. <b>2021</b> , 35, 469-493		0
105	Current status and future perspectives of immunotherapy against urothelial and kidney cancer. <b>2021</b> , 51, 1481-1492		2
104	Overexpression of Pyruvate Dehydrogenase Kinase-3 Predicts Poor Prognosis in Urothelial Carcinoma. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 749142	53	3
103	A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of urothelial cancer. <b>2021</b> , 39, 528-547		
102	Impact of paclitaxel, cisplatin, and gemcitabine as first-line chemotherapy in cisplatin-fit and -unfit patients with advanced/metastatic urothelial carcinoma. <b>2021</b> , 39, 731.e25-731.e32		
101	Clinical Activity of Gemcitabine as a Single Agent and in Combination. <b>2006</b> , 253-288		1
100	Chemotherapy for Metastatic Bladder Cancer. <b>2011</b> , 409-431		2
99	Harnblasenkarzinom. <b>2014</b> , 415-502		2
98	Neoadjuvant versus adjuvant chemotherapy in invasive bladder cancer. <b>1993</b> , 126, 189-205		1
97	Harnblasenkarzinom. <b>1997</b> , 85-178		4
96	Harnblasenkarzinome. <b>1994</b> , 79-157		3
95	Bladder Cancer. <b>2014</b> , 1445-1462.e4		4
94	RADICAL CYSTECTOMY IN REGIONALLY ADVANCED BLADDER CANCER. <b>1992</b> , 19, 713-723		71

93	METASTATIC BLADDER CANCER. <b>1992</b> , 19, 735-746		41
92	SYSTEMIC CHEMOTHERAPY IN REGIONALLY ADVANCED BLADDER CANCER. <b>1992</b> , 19, 747-759		15
91	COMBINED TREATMENT APPROACHES IN REGIONALLY ADVANCED BLADDER CANCER. <b>1992</b> , 19, 761-774		4
90	TREATMENT OF CHEMOTHERAPY-REFRACTORY METASTATIC UROTHELIAL TUMORS. <b>1992</b> , 19, 775-777		6
89	MANAGEMENT OF DISSEMINATED DISEASE IN THE PATIENT WITH BLADDER CANCER. <b>1994</b> , 21, 661-672		4
88	Chemotherapy for Metastatic Bladder Cancer. <b>1992</b> , 6, 195-203		6
87	M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder. <b>1996</b> , 19, 344-8		11
86	Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. <b>1997</b> , 20, 519-21		43
85	Pattern of Metastases in Relation to Characteristics of Primary Tumor and Treatment in Patients with Disseminated Urothelial Carcinoma. <i>Journal of Urology</i> , <b>1996</b> , 111-114	2.5	2
84	SHORTER INTERVAL BETWEEN CYCLES OF CYCLOPHOSPHAMIDE, DOXORUBICIN, CISPLATIN USING RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR FOR UROTHELIAL CANCER [PHASE I/II STUDY. <b>1995</b> , 2, 316-321		2
83	New discoveries in the molecular landscape of bladder cancer. <b>2016</b> , 5, 2875		5
82	Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee. <b>2018</b> , 33, 383-390		7
81	Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options. <b>2020</b> , 35, 834-853		8
80	Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer. <b>2015</b> , 4, 273-82		4
79	Treatment of locally advanced and metastatic bladder cancer. <i>Indian Journal of Urology</i> , <b>2008</b> , 24, 84-94	0.8	4
78	Systemic therapy in bladder cancer. <i>Indian Journal of Urology</i> , <b>2017</b> , 33, 118-126	0.8	6
77	Current use of methotrexate in the treatment of malignancies in adults. <b>2000</b> , 31-48		
76	GEMCITABINE PLUS CISPLATIN FOR ADVANCED TRANSITIONAL CELL CARCINOMA OF THE URINARY TRACT: A PHASE II MULTICENTER TRIAL. <i>Journal of Urology</i> , <b>2000</b> , 53-56	2.5	1

- 75 PHASE II STUDY OF PACLITAXEL AND CISPLATIN FOR ADVANCED UROTHELIAL CANCER. *Journal of Urology*, **2000**, 1538-1542 2.5 2
- 74 Blasencarcinome und Carcinome des Übergangsepithels. *Onkologie Heute*, **2001**, 135-178
- 73 Pharmakologische Therapie des lokal fortgeschrittenen und metastasierten Harnblasenkarzinoms. **2002**, 41-58
- 72 Genitourinary Malignancies: Bladder/Penis/Urethral Cancers. **2003**, 521-530
- 71 Chemoembolization, Infusion, and Embolization. *Medical Radiology*, **2004**, 179-224 0.2
- 70 Genitourinary Oncology. **2006**, 123-130
- 69 Ureter, Bladder, Penis, and Urethra. **2006**, 813-832
- 68 Harnblasenkarzinom. **2006**, 4977-5018
- 67 Carcinoma of the Bladder. **2008**, 1635-1652
- 66 Management of Metastatic Bladder Cancer. **2008**, 377-389
- 65 Nierenbecken- und Harnleiterkarzinom. **2009**, 371-394 2
- 64 Adjuvant Chemotherapy in Bladder Cancer: A Good Concept But Where's the Proof?. **2009**, 239-245 1
- 63 Beyond MVAC: New and Improved Chemotherapeutics. **2009**, 247-262
- 62 Cancer of the Bladder. **2010**, 901-924
- 61 Urothelkarzinom der Harnblase. **2010**, 249-279
- 60 Metastatic Bladder Cancer. 321-328
- 59 Neoplasms of the Kidney and Bladder. **2011**, 1049-1068
- 58 Topoisomerase II Inhibitors: Current Use and Prospects. *Cancer Drug Discovery and Development*, **2012**, 279-307 0.3 1

57 Bladder Cancer. **2012**, 325-354

56 Management of Metastatic and Invasive Bladder Cancer. **2012**, 2355-2374.e6

55 Neo-Adjuvant chemotherapy for invasive transitional cell carcinoma (TCC) of the urinary bladder. **1991**, 97-99

54 Harnblasenkarzinom. **1993**, 433-444

53 Die Immuntherapie des fortgeschrittenen Harnblasenkarzinom. **1993**, 183-188

52 Klinische Wertigkeit von In-vitro-Sensitivitätstests. **1993**, 34-40

51 Systemic treatment of bladder cancer. **1994**, 55-61

50 Harnblasenkarzinom. **1995**, 876-891

49 Review Article. *Journal of Urology*, **1995**, 894-900 2.5

48 Optimal Delivery of Perioperative Chemotherapy. *Journal of Urology*, **1996**, 1241-1245 2.5 1

47 Editorial. *Journal of Urology*, **1996**, 1246-1247 2.5

46 Harnblasenkarzinom. **1997**, 1332-1374

45 The management of bladder cancer a case history. **1997**, 185-189

44 Cisplatin, Ifosfamide, Methotrexate and Vinblastine Combination Chemotherapy for Metastatic Urothelial Cancer. *Journal of Urology*, **1997**, 408-411 2.5 2

43 Cancers of the Urinary Tract. **1998**, 695-722

42 Chemotherapy Before Definitive Treatment for Locally Advanced Bladder Cancer. *Medical Radiology*, **1998**, 221-233 0.2

41 Management of Patients with Metastatic Carcinoma of the Bladder. *Medical Radiology*, **1998**, 297-308 0.2

40 Harnblasenkarzinom. **1998**, 1048-1067

- 39 Advanced transitional cell carcinoma of the upper urinary tract: patterns of failure, survival and impact of postoperative adjuvant radiotherapy. *Journal of Urology*, **1998**, 160, 703-6 2.5 17
- 38 New chemotherapy regimens for metastatic bladder cancer. *Current Opinion in Urology*, **1998**, 8, 413-8 2.8 1
- 37 Genitourinary Malignancies: Bladder, Penis, and Urethral Cancers. **1999**, 829-844
- 36 Chemotherapy. **2015**, 179-189
- 35 Management of Bladder Cancer, Role of Chemotherapy and Controversies Surrounding Its Application. **2015**, 387-403
- 34 Management of Metastatic Bladder Tumours. **2015**, 627-646
- 33 Urothelkarzinom der Nieren und Harnleiter: Therapie. **2015**, 1-31
- 32 Treatment of metastatic bladder cancer. 304-319
- 31 Chemotherapy for metastatic bladder cancer. **2015**, 206-220
- 30 Urothelkarzinom der Nieren und Harnleiter: Therapie. **2016**, 409-430
- 29 Current position of chemotherapy in treating bladder cancer. *Urologie Pro Praxi*, **2016**, 17, 64-68 0.1
- 28 Targeted Therapies and Immunotherapy in Bladder Cancer. **2017**, 111-122
- 27 The Systematic Review of the Efficacy and Safety of Immune Checkpoint Inhibitor in Urological Cancers. *The Korean Journal of Urological Oncology*, **2019**, 17, 75-80 0.1
- 26 Harnblasenkarzinom. **2014**, 415-502 0
- 25 Pharmakologische Therapie des fortgeschrittenen und metastasierten Urothelkarzinoms. **2005**, 51-71
- 24 Systemische Chemotherapie des metastasierten Urothelkarzinoms Eine kritische Analyse. **2005**, 125-138
- 23 Chemotherapy of metastatic transitional cell cancer. **2007**, 197-210
- 22 Chemotherapy for Bladder Cancer. **2007**, 102-123



21	Nierenbecken- und Harnleiterkarzinom. <b>2007</b> , 277-299		
20	Urothelkarzinom der Harnblase. <b>2014</b> , 175-195		0
19	Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease. <i>Clinical Advances in Hematology and Oncology</i> , <b>2017</b> , 15, 466-477	0.6	3
18	Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 710943	5.6	1
17	Curative Effect and Survival Assessment Comparing Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin and Cisplatin as Neoadjuvant Therapy for Bladder Cancer: A Systematic Review and Meta-Analysis.. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 678896	5.3	2
16	Neoadjuvant and adjuvant chemotherapy in bladder cancer. <b>2000</b> , 2, 231-237		
15	Neoadjuvant and Adjuvant Therapy for Muscle-Invasive Bladder Cancer. <b>2022</b> , 349-379		
14	Image_1.TIF. <b>2019</b> ,		
13	Table_1.doc. <b>2019</b> ,		
12	Image_1.tif. <b>2020</b> ,		
11	Image_2.tif. <b>2020</b> ,		
10	Table_1.docx. <b>2020</b> ,		
9	Table_2.docx. <b>2020</b> ,		
8	Table_3.docx. <b>2020</b> ,		
7	Table_4.docx. <b>2020</b> ,		
6	Urothelial Carcinoma (Bladder Cancer and Upper Tracts). <b>2023</b> , 309-329.e4		
5	Controlling Nutritional Status (CONUT) Score and Sarcopenia as Mutually Independent Prognostic Biomarkers in Advanced Urothelial Carcinoma. <b>2022</b> , 14, 5075		0
4	Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives. 039156032211399		0

- 3 Long-Term Outcome of Patients with Stage II and III Muscle-Invasive Urothelial Bladder Cancer after Multimodality Approach. Which Is the Best Option?. **2023**, 59, 50 1
- 2 Immune Checkpoint Inhibitors in Urological Cancers. **2023**, 1-25 0
- 1 Urothelkarzinom der Nieren und Harnleiter: Therapie. **2022**, 1-15 0